~(99)Tc~m-MIBI显像在非霍奇金淋巴瘤化疗疗效评价中的价值

目的探讨99Tcm-MIBI显像在非霍奇金淋巴瘤疗效评价及提示预后方面的临床价值。方法对20例非霍奇金淋巴瘤病人于化疗前后分别行99Tcm-MIBI早期(10 min)与延迟(120 min)双时相显像,计算每例病人早期摄取率(EUR)、延迟期摄取率(DUR)及洗脱率(WR%)并进行比较。对99Tcm-MIBI显像结果进行疗效评价。平均随访时间34个月。结果 8例病人化疗后99Tcm-MIBI显像阴性,达完全缓解(CR)。12例病人化疗后99Tcm-MIBI显像阳性,其中4例达部分缓解(PR),2例处于稳定(SD)状态,6例进展(PD)。将病人分为化疗有效组(CR+PR)12例,疗效不佳组(SD+PD)8例。20例病人化疗后DUR明显低于化疗前(1.2±0.7∶2.9±1.2,P0.05)。化疗有效组与疗效不佳组相比,前者化疗前的DUR值高于后者(2.9±1.2∶1.5±0.9,P0.05),WR%低于后者(21.9±2.4∶42.7±5.6,P0.05),而前者化疗后的DUR值低于后者(1.0±0.2∶2.0±0.3,P0.05)。结论 99Tcm-MIBI作为一种功能性显像,有助于预测、评价非霍奇金淋巴瘤病人的疗效及预后。

The clinical value of the 99Tcm-MIBI scintigraphy in predicting the chemotherapy response of non-Hodgkin's lymphoma

Objective To investigate the usefulness of ⁹⁹Tc^m-MIBI scintigraphy in assessing the chemotherapy response, predicting prognosis of non-Hodgkin’s lymphoma. Methods Twenty patients underwent early (10 min) and delayed (120 min) ⁹⁹Tc^m-MIBI scintigraphy before and after chemotherapy. The early uptake rate(EUR), delay uptake rate(DUR), and washout rate(WR%) were calculated. Clinical response was assessed. The average follow-up time was 34 months. Results After chemotherapy, 8 patients showed complete remission(CR) with ⁹⁹Tc^m-MIBI negative and 12 patients had positive imaging. 4 of them presented partial remission (PR), 2 were in stable disease (SD) and 6 were in progressive disease (PD). Patients were divided into two groups, 12 in partial or complete response（CR+PR）and 8 in stable or progressive disease （SD+PD）group. There was statistically difference in DUR before and after chemotherapy in all the 20 patients (2.9±1.2 vs. 1.2±0.7, P<0.05). Before chemotherapy，the DUR was significantly higher in partial or complete response group than that in stable or progressive disease group (2.9±1.2 vs. 1.5±0.9, P<0.05). The WR% was significantly lower in partial or complete response group than that in stable or progressive disease group (21.9±2.4 vs. 42.7±50.6, P<0.05). After chemotherapy the DUR was significantly lower in partial or complete response group than that in stable or progressive disease group (1.0±0.2 vs. 2.0±0.3, P<0.05). Conclusion As a functional imaging, ⁹⁹Tc^m-MIBI scintigraphy is helpful in assessing the chemotherapy response andpredicting prognosis of non-Hodgkin’s lymphoma.